Copyright © 2005 Elsevier B.V. All rights reserved.
Review
Bridging advanced glycation end product, receptor for advanced glycation end product and nitric oxide with hormonal replacement/estrogen therapy in healthy versus diabetic postmenopausal women: A perspective
Received 8 February 2005;
Abstract
Cardiovascular diseases (CVD) are the most significant cause of death in postmenopausal women. The loss of estrogen biosynthesis with advanced age is suggested as one of the major causes of higher CVD in postmenopausal women. While some studies show beneficial effects of estrogen therapy (ET)/hormonal replacement therapy (HRT) in the cardiovascular system of healthy postmenopausal women, similar studies in diabetic counterparts contradict these findings. In particular, ET/HRT in diabetic postmenopausal women results in a seemingly detrimental effect on the cardiovascular system. In this review, the comparative role of estrogens is discussed in the context of CVD in both healthy and diabetic postmenopausal women in regard to the synthesis or expression of proinflammatory molecules like advanced glycation end products (AGEs), receptor for advanced glycation end products (RAGEs), inducible nitric oxide synthases (iNOS) and the anti-inflammatory endothelial nitric oxide synthases (eNOS). The interaction of AGE–RAGE signaling with molecular nitric oxide (NO) may determine the level of reactive oxygen species (ROS) and influence the overall redox status of the vascular microenvironment that may further determine the ultimate outcome of the effects of estrogens on the CVD in healthy versus diabetic women.
Keywords: AGE; RAGE; Estrogen; HRT; ET; Diabetes; NO; ROS; Postmenopausal women
Article Outline
- 1. Background
- 2. Role of estrogen in the context of cardiovascular disorders in healthy premenopausal and postmenopausal women
- 3. Estrogen and cardiovascular disorders in premenopausal diabetic women
- 4. Paradox of the effect of HRT on the cardiovascular disorders in postmenopausal diabetic women: clinical studies
- 5. Paradox of the recent in vitro experimental results on estrogen and cardiovascular disorders
- 6. Functional abnormalities of vascular system in diabetes and its relationship with estrogen
- 7. Advanced glycation end products (AGEs) as a vascular proinflammatory molecule
- 8. Receptor-independent actions of advanced glycation end products (AGEs) in vascular dysfunction
- 9. Receptor-dependent action of advanced glycation end products (AGEs) in vascular dysfunction
- 10. AGE–RAGE interaction causes subcellular signaling leading to the generation of ROS and vascular dysfunction
- 11. Effect of estrogen as an inducer of AGE–RAGE signaling
- 12. Possible role of estrogen in RAGE signaling in homeostasis versus pathophysiological conditions
- 13. Bridging of NO and ROS as effector molecules with AGE–RAGE signaling in diabetes
- 14. Effects of estrogen on nitric oxide signaling in healthy versus diabetic subjects
- 15. The influence of overall oxidative stress on the vascular system of diabetic subjects
- 16. Role of estrogen in controlling the overall oxidative stress of diabetic vasculature
- 17. Conclusion
- Acknowledgements
- References






E-mail Article
Add to my Quick Links

Cited By in Scopus (4)







